Royalty Pharma

Royalty Pharma is a biopharmaceutical company based in New York City that purchases economic interests in marketed and late stage biopharmaceutical products from life sciences organizations.[2] Royalty Pharma funds innovation in life sciences both directly and indirectly: directly when it partners with life sciences companies to co-develop and co-fund products in late-stage clinical trials, and indirectly when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations and inventors).[3]

Royalty Pharma
TypePublic
NASDAQ: RPRX
IndustryBiopharmaceuticals
Founded1996
HeadquartersNew York City, US
Key people
Pablo Legorreta (Founder) [1]
Websitewww.royaltypharma.com

History

Royalty Pharma was founded in 1996 by Pablo Legorreta.[4]

Legorreta, chief executive officer (CEO), attended Universidad Iberoamericana and is a board member for Epizyme Inc. and Giuliani S.p.A.[5]

In 2004, Royalty Pharma acquired Memorial Sloan Kettering Cancer Center’s royalty on Amgen's Neupogen / Neulasta for $263 million in cash.[6]

In 2007, Royalty Pharma acquired from Northwestern University its worldwide royalty interest in Pfizer’s Lyrica for $700 million in cash.[7]

In 2014, Royalty Pharma announced a $3.3 billion royalty transaction with Cystic Fibrosis Foundation Therapeutics.[8]

In February 2017, Royalty Pharma purchased a portion of the potential royalty due to Cytokinetics from Amgen on worldwide sales of omecamtiv mecarbil.[9]

In 2017, Royalty Pharma acquire Perrigo’s Tysabri royalty stream for $2.85 billion.[10]

In June 2020, Royalty Pharma completed its initial public offering (IPO) on the NASDAQ.[2]

Pharmaceutical royalties

Crysvita, purchased from Ultragenyx Pharmaceutical in 2019, treats X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons.[11]

Humira, purchased from AstraZeneca in 2006, is used in adults to reduce the signs and symptoms of moderate to severe rheumatoid arthritis.[11]

Lyrica, purchased from Northwestern University in 2007, is indicated to treat diabetic nerve pain, post shingles pain andfibromyalgia.[12]

Tazverik, purchased from Eisai Co., LTD. is a treatment of epithelioid sarcoma and follicular lymphoma.[13]

Xtandi, purchased from UCLA in 2016, is a treatment for men with metastatic castration-resistant prostate cancer (CRPC).[14]

References
  1. "Meet The Secretive Wall Street Investor With The Billion Dollar Medicine Cabinet". Forbes. June 12, 2020.
  2. "Billionaire Pablo Legorreta's Big Royalty Pharma IPO Soars". Forbes. June 16, 2020.
  3. "Royalty Pharma: An Interesting Business". Seeking Alpha. June 21, 2020.
  4. "Pablo G Legorreta". Bloomberg. July 8, 2020.
  5. "Pablo Legorreta". The New York Academy of Sciences. July 7, 2020.
  6. "Cashing in on Royalties". Modern Healthcare. August 29, 2004.
  7. "Northwestern fetches $700 million for drug". Chicago Tribune. December 19, 2007.
  8. "Cystic Fibrosis Foundation Sells Drug Royalties for $3B". Bloomberg. November 19, 2014.
  9. "Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil". Reuters. February 2, 2017.
  10. "Perrigo to Sell Multiple-Sclerosis Drug Royalties for Up to $2.85 Billion". The Wall Street Journal. February 27, 2017.
  11. "Ultragenyx sells European royalty stake in rare disease drug for $320M". BioPharma Dive. December 18, 2019.
  12. "FDA opens US to Lyrica generics". LSIPR. July 24, 2019.
  13. "Epizyme's first-in-class Tazverik launch on track to top Gilead's Zydelig: analyst". Fierce Pharma. February 25, 2020.
  14. "UCLA will get hundreds of millions for rights to prostate cancer drug". Los Angeles Times. March 4, 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.